HRT Financial’s Allogene Therapeutics ALLO Stock Holding History

HRT Financial’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$47K	Sell	19,605 -53,146	-73%	-$107K	﹤0.01%	3462
2025 Q4	$99K	Sell	72,751 -59,780	-45%	-$78.9K	﹤0.01%	2791
2025 Q3	$164K	Buy	+132,531	New	+$158K	﹤0.01%	2451
2024 Q1	–	Sell	-235,333	Closed	-$755K	–	2243
2023 Q4	$755K	Buy	+235,333	New	+$667K	0.01%	1130
2023 Q2	–	Sell	-104,172	Closed	-$514K	–	2403
2023 Q1	$514K	Buy	+104,172	New	+$668K	0.01%	1361
2022 Q4	–	Sell	-110,259	Closed	-$1.19M	–	2423
2022 Q3	$1.19M	Buy	+110,259	New	+$1.5M	0.01%	816
2022 Q1	–	Sell	-10,675	Closed	-$159K	–	3032
2021 Q4	$159K	Buy	+10,675	New	+$188K	﹤0.01%	2616
2021 Q2	–	Sell	-36,018	Closed	-$1.27M	–	2794
2021 Q1	$1.27M	Buy	+36,018	New	+$1.21M	0.01%	921

Other funds holding ALLO

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HRT Financial's ALLO Position: Q1 2026 in Review

HRT Financial reduced its Allogene Therapeutics (ALLO) stake by 73% in Q1 2026, selling an estimated $107K and leaving 19,605 shares worth $47K. The position accounts for ﹤0.01% of the portfolio, ranked #3462.

HRT Financial first reported a position in ALLO in Q1 2021 and has held it in 8 quarters since. The position peaked at $1.27M in Q1 2021. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

HRT Financial held 19,605 shares of Allogene Therapeutics worth $47K as of Q1 2026.
HRT Financial sold 53,146 Allogene Therapeutics shares in Q1 2026, an estimated $107K.
Allogene Therapeutics made up ﹤0.01% of HRT Financial's portfolio in Q1 2026, its #3462 holding.
HRT Financial first reported a position in Allogene Therapeutics in Q1 2021 and has held it in 8 quarters since.
HRT Financial's Allogene Therapeutics position peaked at $1.27M in Q1 2021.
208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.